Outset Medical (NASDAQ:OM - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($1.76) per share and revenue of $29.40 million for the quarter. Outset Medical has set its FY 2025 guidance at EPS.
Outset Medical (NASDAQ:OM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($3.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($2.69). The business had revenue of $29.75 million for the quarter, compared to analyst estimates of $27.81 million. Outset Medical had a negative return on equity of 143.62% and a negative net margin of 98.74%.
Outset Medical Price Performance
OM traded down $1.02 during trading on Friday, reaching $15.04. 449,042 shares of the stock were exchanged, compared to its average volume of 217,181. The business's 50 day moving average price is $19.16 and its two-hundred day moving average price is $14.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 8.37 and a quick ratio of 6.74. The company has a market capitalization of $266.54 million, a price-to-earnings ratio of -0.52 and a beta of 2.15. Outset Medical has a 1 year low of $5.85 and a 1 year high of $53.92.
Analyst Ratings Changes
OM has been the topic of a number of research analyst reports. Wall Street Zen upgraded Outset Medical from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Royal Bank Of Canada reiterated a "sector perform" rating and set a $21.00 target price (up from $14.00) on shares of Outset Medical in a research report on Wednesday, May 21st. Scotiabank upgraded Outset Medical to a "strong-buy" rating in a research report on Thursday, May 15th. Finally, BTIG Research set a $37.00 price objective on Outset Medical and gave the company a "buy" rating in a research report on Monday, July 14th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.50.
Read Our Latest Report on OM
Outset Medical Company Profile
(
Get Free Report)
Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Further Reading
Before you consider Outset Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outset Medical wasn't on the list.
While Outset Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
